Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

United States Market Report for Psoriasis Immunology Drugs 2018 - Research and Markets

Research and Markets
Posted on: 02 Nov 17

The "US Market Report for Psoriasis Immunology Drugs 2018 - MedCore" report has been added to Research and Markets' offering.

General Report Contents

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

The typical life cycle of a healthy skin cell is about one month, but in people with psoriasis this process may take just a few days. This rapid overproduction leads to the build-up of skin cells because they do not have time to fall off. In most cases psoriasis can be diagnosed during the skin examination by dermatologist. In some cases, psoriasis can look like eczema and may require additional diagnostic tests, including biopsy, blood tests and X-rays.

Treating options vary depending on the level of pain and swelling. Non-steroidal anti-inflammatory drugs (ibuprofen, Motrin or Advil) or naproxen (Aleve) are used as initial treatment. In more severe cases disease modifying anti-rheumatic drugs (DMARDs) may be prescribed. DMARDs include sulfasalazine, methotrexate, cyclosporine and leflunomide. Other options are biologic medications, including HUMIRA (adalimumab), Enbrel (etanercept), SIMPONI (golimumab), CIMZIA (certolizumab), STELARA (ustekinumab) and REMICADE (infliximab) that are indicated for the both arthritis and skin psoriasis treatment.

The most recent developments include Cosentyx (secukinumab), a biologic injection manufactured by Novartis for the treatment of psoriatic arthritis and launched in 2015. Cosentyx is currently approved in more than 75 countries for the treatment of moderate-to-severe plaque psoriasis. The product is available in the European Union countries, Japan, Switzerland, Australia, the United States and Canada.

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action

3.1 Introduction

3.1.1 Tumor Necrosis Factor (Tnf)

3.1.2 B-Cell Inhibitors

3.1.3 Interleukin Inhibitors

3.1.4 Janus Kinase Inhibitors

3.1.5 Co-Stimulation Modulators

4. Product Assessment

4.1 Key Marketed Products

4.2 Key Products in Pipeline

4.3 Products in Development By Core Companies

5. Country Profile

5.1 United States

5.1.1 Population And Demographics

5.1.2 Treatment Size Analysis for 2017

5.1.3 Drug Cost Analysis

6. Psoriasis Market

6.1 Introduction

6.2 Market Overview

6.3 Trend Analysis

6.4 Competitive Analysis

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • UCB S.A.

For more information about this report visit https://www.researchandmarkets.com/research/vt58cp/us_market_report

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005925/en/

Business Wire
www.businesswire.com

Last updated on: 02/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.